



Programme at a Glance - Thursday, May 24th, 2018

Immune-mediated renal diseases: old drugs and new WG: The challenge of decreasing cardiovascular was are the challenges and length are the challenges are the chal	
CME 1 - IWG: Immune-mediated renal diseases: old drugs and new disease entities 12.00-12.15 CME 1 - IWG: Immune-mediated renal diseases: old drugs and new disease entities CME 3 - DESCARTES WG: Improving variable transplantation: what are the challenges and opportunities ahead? CME 5 - ERA-EDTA Registry: Cross-talk in renal epidemiology (9.15-12.00) CME 6 - ERBP from guidelines to practice (9.15-12.00) CME 1 - Euro-PD: Integrating dialysis care: getting the best from home therapies CME 1 - Euro-PD: Integrating dialysis care: getting the best from home therapies and size as complications and surveillance, including practical demonstration of fistula imaging (12.45-16.00) CME 17 - ERA-EDTA & EULIS CME 18: Ethical aspects in dialysis and kidney transplantation in the variable with the complex of the second content of the complex o	IVIU
Immune-mediated renal diseases: old drugs and new disease entities WG: Improving of decreasing cardiovascular mortality in CKD WG: Improving transplantation: what are the challenges and opportunities ahead? WG: Improving transplantation: what are the challenges and opportunities ahead? WG: Improving transplantation: what are the challenges and opportunities ahead? WG: Insulin resistance and renal disease CME 6 - ERBP from guidelines to practice (9.15-12.00) Physiology to clinic Integrating dialysis care: getting the best from home therapies CME 11 - Euro-PD: Integrating dialysis care: getting the best from home therapies CME 11 - Euro-PD: Integrating dialysis care: getting the best from home therapies CME 13 - CKD-MBD (12.45-16.00) Integrating dialysis care: getting the best from home therapies CME 17 - ERA-EDTA & EULIS CME 17 - ERA-EDTA & EULIS CME 18: Ethical aspects in dialysis and acid-base balance: from physiology to clinic Integrating dialysis care: getting the best from home therapies CME 17 - ERA-EDTA & EULIS CME 18: Ethical aspects in dialysis and kidney transplantation in the CME 12 - ERA-EDTA & EULIS CME 18: Ethical aspects in dialysis and kidney transplantation in the CME 14 - WG: MG: MG: MG: MG: MG: MG: MG: MG: MG: M	
renal diseases: old drugs and new disease entities of decreasing cardiovascular mortality in CKD opportunities ahead? Itansplantation: what are the challenges and opportunities ahead? Itansplantation opportunities ahead? Itanspla	E 9 - EUTox 3: Uremic
12.15-14.15 CME 12 - Rheumatology for nephrologists (12.45-16.00) 14.15-14.30 14.30-16.30 CME 13 - CKD-MBD WG: Emerging insights in CKD-MBD (12.45-16.00) CME 14 - WGIKD WG: What's new in rare kidney diseases? (12.45-16.00) CME 15 - Onconephrology (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) CME 17 - ERA-EDTA & EULIS CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 17 - ERA-EDTA & EULIS CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 17 - ERA-EDTA & EULIS CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 17 - ERA-EDTA & EULIS CME 11 - Euro-PD: Integrating dialysis care: getting the best from home theraples CME 17 - ERA-EDTA & EULIS	toxins: sources and alterations leading to the uremic state
CME 12 - Rheumatology for nephrologists (12.45-16.00) 14.15-14.30 14.30-16.30 CME 13 - CKD-MBD WG: What's new in rare kidney diseases? (12.45-16.00) CME 14 - WGIKD WG: What's new in rare kidney diseases? (12.45-16.00) CME 15 - Onconephrology (12.45-16.00) CME 15 - Onconephrology (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Rheumatology for nephrologists (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) CME 16 - ERN WG: Presentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) CME 17 - ERA-EDTA & EULIS CME 18: Ethical aspects in dialysis and kidney transplantation in the	
Rheumatology for nephrologists (12.45-16.00) WG: Emerging insights in CKD-MBD (12.45-16.00) WG: What's new in rare kidney diseases? (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Roccess, access complications and surveillance, including practical demonstration of fistula imaging (12.15-16.30) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00) Resentation of the 2018 KDOQI Clinical Practice Guideline for Nutrition in CKD (12.45-16.00)	
tor nephrologists (12.45-16.00) 14.15-14.30 14.30-16.30 Tare kidney diseases? (12.45-16.00) Tare kidne	
14.30-16.30 (12.45-16.00) (12.	
14.15-14.30 14.30-16.30 Table 15.10 (12.45-16.00) Table 16.10 (12.45-16.00) Table 16.10 (12.45-16.00) Table 16.10 (12.45-16.00) Table 16.10 (12.45-16.00) Complications and surveillance, including practical demonstration of fistula imaging (12.15-16.30) CME 17 - ERA-EDTA & EULIS CME 17 - ERA-EDTA & EULIS Table 17 - ERA-EDTA & EULIS Table 18: Ethical aspects in dialysis and kidney transplantation in the	
14.30-16.30 (12.45-16.00) and surveillance, including practical demonstration of fistula imaging (12.15-16.30) (12.15-16.30) CME 18: Ethical aspects in dialysis and kidney transplantation in the	
demonstration of fistula imaging (12) 15-16 (20) ERA-EDTA & EULIS aspects in dialysis and kidney transplantation in the	
fistula imaging and kidney transplantation in the	
(12 15-16 30) Transplantation in the	
- County	
17.00-18.15 Welcome Ceremony	
+PL Toni	
Cathomen: Gene	
editing: powerful new	
tool for nephrology research and therapy	
16.00-20.00 Exhibition	

LEGENDA

Fluids and electrolytes,	Hereditary disorders,	Glomerular diseases	Chronic Kidney Disease:	End Stage	Home therapies,	Transplantation	Hypertension,	Acute Kidney Injury
tubular transport,	development, pregnancy,	and general	pathophysiology, epidemiology,	Renal Disease	peritoneal	and	diabetes,	and intensive care
physiology	paediatric nephrology	clinical nephrology	prevention, progression, aging	and dialysis	dialysis	immunology	vascular diseases	nephrology





Programme at a Glance - Friday, May 25th, 2018

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
	selected topics from 2017/18	S 4.9 CKD - new therapeutic approaches		S 6.2 - Optimising clinical outcomes and technique survival	S 5.2 - The non- dialysis pathway in ESRD	FC 01 - Salt and related issues	FC 02 - Cardiovascular complications in dialysis	FC 03 - History of nephrology		
9.30-10.45	Posters, coffee break a	and exhibition visit								PACE-CME - BOEHRINGEI INGELHEIM / LILLY
	PL 2 - Klaus Olgaard: New paradigms of the kidney - Vascular- bone axis in CKD									
11.30-11.45										
11.45-13.15	S 0.2 - Late Breaking Clinical Trials	S 4.2 - Progression of chronic kidney disease – hot issues beyond blood pressure and renin- angiotensin system	S 6.3 - Optimising fluid management in PD patients	S 5.9 - DOPPS - The sweet truth: Optimizing care in advanced CKD and dialysis with a focus on diabetic patients	S 3.6 - Glomerular disease in the omics era	FC 04 - AKI experimental	FC 05 - Clinical nephrology 1	FC 06 - CKD rehabilitation	FC 07 - Clinical hypertension 1	
3.15-14.45		VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA	BAXTER HEALTHCARE	FRESENIUS MEDICAL CARE	AMGEN EUROPE	DANONE NUTRICIA RESEARCH	ASTRAZENECA PHARMACEUTICALS LP	SANOFI-GENZYME	MSD	PACE-CME - RESVERLOGIX
	S 0.4 - ASN Highlights	vasculitis - therapy	S 5.3 - Uremic toxicity - New insights	S 8.2 - A new life for sodium in Nephrology		FC 08 - Renal pathology 1	FC 09 - Biomarkers in CKD	FC 10 - Bone disease in HD	FC 11 - Transplantation epidemiology	
	Posters, coffee break a									
17.00-18.30	S 8.3 - Diabetic nephropathy	S 5.7 - Treatment of CKD-MBD	Nephrology (JSN)	\$ 7.3 - Expanding the donor pool (deceased and live donors) KPD, ABOi, machine perfusion	S 4.8 - n-3 PUFA in CKD: Does it matter?	FC 12 - Clinical nephrology 2	FC 13 - Genetic diseases	FC 14 - CKD risk and progression	FC 15 - AKI clinical 1	
18.45-19.45							SIEMENS HEALTHINEERS			ZYDUS TRANS-IMMUNE (A DIVISION OF CADILA HEALTHCARE)
EGENDA									·	
Fluids and ele tubular tra physiol	ansport, developm	nent, pregnancy,		Chronic Kidney Disease: athophysiology, epidemiologorevention, progression, agir		Home thera peritone dialysis	al	and	dypertension, diabetes, scular diseases	Acute Kidney Injury and intensive care nephrology





Programme at a Glance - Saturday, May 26th, 2018

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
		S 5.5 - Challenges in CKD	S 4.1 - Update in plasmapheresis for treating kidney diseases	S 2.2 - Pediatric nephrology	S 9.2 - AKI in various circumstances	FC 16 - Anaemia in CKD	clinical	FC 18 - Transplantation treatment		
09.30-10.45	Poster session, coffee	break and exhibition vis	sit				ASAHI KASEI MEDICAL EUROPE	OTSUKA PHARMA- CEUTICAL EUROPE		SHIRE INTERNATIONAL
	PL 3 - Bruce Sullenger: From the RNA world to the clinic: RNAs as drugs and drug targets									
11.30-11.45	Coffee break and exhib	nition visit								
	S 4.7 - CKD as a public health priority: organizational models		0.8 - ERA-EDTA & European Society for Paediatric Nephrology (ESPN)	Replacement Therapy in	0.1 - ERA-EDTA Registry Symposium	FC 19 - Glomerulo- nephritis 1	FC 20 - CKD epidemiology	FC 21 - CKD-MBD		
13.15-14.45		VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA		ALEXION PHARMACEUTICALS	B.BRAUN AVITUM	ASTRAZENECA PHARMACEUTICALS LP	TERUMO BCT	NXSTAGE MEDICAL	MEDICE ARZNEIMITTEL PÜTTER	AMICUS THERAPEUTICS
	S 6.4 - Home haemodialysis in Europe 2018	S 5.6 - Cardiovascular calcifications in CKD	S 4.6 - Focus on surrogate end-points in Nephrology		S 1.2 - Mitochondria: critical players in kidney disorders	FC 22 - Renal pathology 2		FC 24 - Extracorporeal treatment	FC 25 - Inflammation in CKD	
16.30-17.00	Posters, coffee break a	nd exhibition visit								
	findings in ADPKD	S 5.1 - Scheduling dialysis and hemodiafiltration in 2018: a new portfolio?	S 7.2 - Humoral immunity (HLA and non-HLA)	S 4.3 - New biomarkers of CKD progression	FC 26 - Cell biology	FC 27 - Glomerulo- nephritis 2	FC 28 - AKI Clinical 2	FC 29 - Outcome in dialysis		

LEGENDA

ds and electrolytes, ubular transport, paediatric nephrology paediatric nephrology Glomerular diseases pathophysiology, epider clinical nephrology prevention, progression	gy, Renal Disease peritoneal	Transplantation and immunology	Hypertension, diabetes, vascular diseases	Acute Kidney Injury and intensive care nephrology
--	------------------------------	--------------------------------------	---	---





Programme at a Glance - Sunday, May 27th, 2018

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
	S 5.8 - The diagnosis of Heart Failure in End Stage Kidney Disease (ESKD): a lingering dilemma	nephropathy: from genes to therapeutic controversies	S 7.4 - Post transplantation diabetes mellitus - relation to obesity and new options/ challenges	S 9.1 - AKI biomarkers and risk factors	0.7 - ERA-EDTA & European Society of Hypertension (ESH)	S 2.3 - Pregnancy, CKD and hypertension	S 4.4 - Interstitial fibrosis and mechanisms of CKD progression	FC 30 - Nutrition in CKD	FC 31 - Vascular access	FC 32 - Peritoneal dialysis
09.30-09.45	Break		,							
09.45-10.30	PL 4 - Marcello Tonelli: Epidemiology of kidney disease									
10.30-10.45	Coffee break									
10.45-12.15	S 5.4 - New methods of anaemia management in CKD patients	S 7.5 - Risk profiling in renal transplant patients	S 3.4 - Rituximab in immune mediated glomerular diseases: one drug does not fit all	S 4.5 - Controversy: too much Nephrology?	S 6.1 - Lessons from International Databases (in collaboration with ISPD)	S 1.3 - APOL1 impact in kidney disease	FC 33 - Renal development and cystic diseases	FC 34 - Acid-base balance and uric acid	FC 35 - Diabetes basic research	FC 36 - Paediatric nephrology
12.15-12.30	Break									
12.30-14.00	SS 1 - Nephrology Pearls									

LEGENDA

Fluids and electrolytes, Hereditary disorders, tubular transport, paediatric nephrology physiology paediatric nephrology Clinical nephrology prevention, progression, aging Chronic Kidney Disease: End Stage Part Stage Par	Home therapies,	Transplantation	Hypertension,	Acute Kidney Injury
	peritoneal	and	diabetes,	and intensive care
	dialysis	immunology	vascular diseases	nephrology